The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.

OBJECTIVE To estimate the overall efficacy and optimal use of the nicotine patch for treating tobacco dependence. DATA SOURCES Nicotine patch efficacy studies published through September 1993, identified through MEDLINE, Psychological Abstracts, and Food and Drug Administration new drug applications. STUDY SELECTION Double-blind, placebo-controlled nicotine patch studies of 4 weeks or longer with random assignment of subjects, biochemical confirmation of abstinence, and subjects not selected on the basis of specific diseases (eg, coronary artery disease). DATA EXTRACTION Pooled abstinence rates and combined odds ratios (ORs) at end of treatment and 6-month follow-up were examined overall and in terms of patch type (16-hour vs 24-hour), patch treatment duration, dosage reduction (weaning), counseling format (individual vs group), and intensity of adjuvant behavioral counseling. DATA SYNTHESIS Across 17 studies (n = 5098 patients) meeting inclusion criteria, overall abstinence rates for the active patch were 27% (vs 13% for placebo) at the end of treatment and 22% (vs 9% for placebo) at 6 months. The combined ORs for efficacy of active patch vs placebo patch were 2.6 at the end of treatment and 3.0 at 6 months. The active patch was superior to the placebo patch regardless of patch type (16-hour vs 24-hour), patch treatment duration, weaning, counseling format, or counseling intensity. The 16-hour and 24-hour patches appeared equally efficacious, and extending treatment beyond 8 weeks did not appear to increase efficacy. The pooled abstinence data showed that intensive behavioral counseling had a reliable but modest positive impact on quit rates. CONCLUSIONS The nicotine patch is an effective aid to quitting smoking across different patch-use strategies. Active patch subjects were more than twice as likely to quit smoking as individuals wearing a placebo patch, and this effect was present at both high and low intensities of counseling. The nicotine patch is an effective smoking cessation aid and has the potential to improve public health significantly.

[1]  Timothy B. Baker,et al.  The Effectiveness of the Nicotine Patch for Smoking Cessation. A Meta-analysis , 1995 .

[2]  B. Rimer,et al.  Use of transdermal nicotine in a state-level prescription plan for the elderly. A first look at 'real-world' patch users. , 1994, JAMA.

[3]  R. Hurt,et al.  Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. , 1994, JAMA.

[4]  D. Wetter,et al.  Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. , 1994, Chest.

[5]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[6]  A. Cepeda-Benito,et al.  Meta-analytical review of the efficacy of nicotine chewing gum in smoking treatment programs. , 1993, Journal of consulting and clinical psychology.

[7]  J. Hughes.  Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. , 1993, Journal of consulting and clinical psychology.

[8]  S. Leischow,et al.  Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. , 1993, Archives of internal medicine.

[9]  E. Levin,et al.  The nicotine patch in smoking cessation. A randomized trial with telephone counseling. , 1993, Archives of internal medicine.

[10]  P. Hauri,et al.  Serum nicotine and cotinine levels during nicotine‐patch therapy , 1993, Clinical pharmacology and therapeutics.

[11]  D. Mant,et al.  Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. Imperial Cancer Research Fund General Practice Research Group. , 1993, BMJ.

[12]  G. Gustavsson,et al.  Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. , 1993, BMJ.

[13]  T. Mcafee,et al.  Transdermal nicotine: clarifications, side effects, and funding. , 1993, JAMA.

[14]  J. Hughes,et al.  Transdermal Nicotine for Smoking Cessation. , 1993 .

[15]  M. Fiore,et al.  Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. , 1992, JAMA.

[16]  Cox Jl,et al.  Transdermal nicotine replacement and smoking cessation. , 1992 .

[17]  J. Hollis,et al.  Patient referral to a smoking cessation program: who follows through? , 1992, The Journal of family practice.

[18]  Frederick Mosteller,et al.  Some Progress and Problems in Meta-Analysis of Clinical Trials , 1992 .

[19]  K. Dickersin,et al.  Meta-analysis: state-of-the-science. , 1992, Epidemiologic reviews.

[20]  A. Biglan,et al.  Transdermal Nicotine for Smoking Cessation: Six-Month Results From Two Multicenter Controlled Clinical Trials , 1991 .

[21]  P. Tønnesen,et al.  A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. , 1991, The New England journal of medicine.

[22]  Alan Ross,et al.  The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome , 1991 .

[23]  S. Rennard,et al.  Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double-blind study. , 1991, Archives of internal medicine.

[24]  M. Jarvik,et al.  Transdermal nicotine and smoking behavior in psychiatric patients. , 1991, The American journal of psychiatry.

[25]  R. Hurt,et al.  Nicotine-replacement therapy with use of a transdermal nicotine patch--a randomized double-blind placebo-controlled trial. , 1990, Mayo Clinic proceedings.

[26]  Michael C. Fiore,et al.  Methods used to quit smoking in the United States. Do cessation programs help , 1990 .

[27]  J. Devane,et al.  Clinical and pharmacokinetic properties of a transdermal nicotine patch , 1990, Clinical pharmacology and therapeutics.

[28]  E. Levin,et al.  Transdermal nicotine facilitates smoking cessation , 1990, Clinical pharmacology and therapeutics.

[29]  T. Abelin,et al.  Effectiveness of a transdermal nicotine system in smoking cessation studies. , 1989, Methods and findings in experimental and clinical pharmacology.

[30]  T. Abelin,et al.  CONTROLLED TRIAL OF TRANSDERMAL NICOTINE PATCH IN TOBACCO WITHDRAWAL , 1989, The Lancet.

[31]  M. Horstmann,et al.  Combination of behavioral smoking cessation with transdermal nicotine substitution. , 1989, Addictive behaviors.

[32]  R N Battista,et al.  Attributes of successful smoking cessation interventions in medical practice. A meta-analysis of 39 controlled trials. , 1988, JAMA.

[33]  H. Sacks,et al.  META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS OF NICOTINE CHEWING-GUM , 1987, The Lancet.

[34]  L. Hedges,et al.  Statistical Methods for Meta-Analysis , 1987 .

[35]  W. Conover.  Statistical Methods for Rates and Proportions , 1974 .

[36]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.